Bradmer gets European approval for new patent

By Elaine Rigoli

Tampa, Fla., June 6 - Bradmer Pharmaceuticals, Inc. said the European Patent Office has issued a letter of allowance for a patent titled "Radioconjugation of Internalizing Antibodies" to the company's license partner Duke University.

The patent relates to the composition of antibody conjugate materials and the methods to enhance and preserve the attachment of radioactive molecules to therapeutic antibodies that are taken into certain diseased cells and subsequently kill them.

A corresponding patent with a similar description was issued by the U.S. Patent and Trademark Office, as U.S. patent number 6,426,400, in July 2002.

In February 2006, Duke University was issued a second patent, U.S. patent number 6,998,106, which describes numerous additions and improvements to the conjugation methods, according to a news release.

"Protecting the proprietary technology related to our novel therapies is a critical long-term component of our corporate strategy and growth opportunities. This progress on the patents in Europe and the United States demonstrates our commitment to build a comprehensive portfolio of innovative targeted antibody therapies," chief executive officer Mark C. Rogers said in the release.

Bradmer is a Toronto-based biotechnology company focused on the development and commercialization of new cancer therapies.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.